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United Kingdom initiated its clinical guidelines program in 2001 and
more than 200 guidelines have been produced to date. As with most of
NICE’s other programs, the clinical guidelines program also must take
into account the relative costs and beneﬁts of interventions when
deciding whether to recommend them. The three main advantages of
the program are that 1) it represents an important collaboration with
the medical profession, thereby increasing the likelihood of recom-
mendations being adopted; 2) the guidelines provide an opportunity
to review all aspects of the clinical pathway, rather than focusing on
only the adoption of a new technology; and 3) the guidelines offer the
potential to discuss disinvestment as well as new investment. All the
guidelines contain a systematic review of the relevant economic
evaluation literature, and the 12 guidelines published from Januaryee front matter Copyright & 2016, International S
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ndence to: Michael Drummond, Centre for Health1 to August 31, 2015, contain 28 de novo economic analyses. The main
challenges encountered in the guidelines program are that 1) there is
an inevitable tension in advising on the quality of care that individual
patients could expect while recognizing the broader public health
objectives of equity, fairness, and efﬁciency; 2) the impact of econom-
ics is sometimes lessened because of the lack of time to conduct de
novo analyses; and 3) unlike NICE’s technology appraisal program, the
adoption of recommendations is not mandatory for the UK National
Health Service.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Background to the Clinical Guidelines Program of the
National Institute for Health and Care Excellence
The clinical guidelines program is one of several programs
operated by the National Institute for Health and Care Excellence
(NICE) in the United Kingdom. Others include programs on
technology appraisal, public health, social care, diagnostics,
medical technology (devices), and interventional procedures.
One of the distinctive features of the clinical guidelines program
is that it focuses on improving the present standard of care,
whereas most of the other programs focus on assessing new
technologies entering the National Health Service (NHS) in the
United Kingdom.
NICE has a strong commitment to cost-effectiveness. Its
procedures state that “[t]hose developing clinical guidelines, tech-
nology appraisals or public health guidance must take into account
the relative costs and beneﬁts of interventions (their ‘cost
effectiveness’) when deciding whether or not to recommend
them” [1]. But “[d]ecisions about whether to recommend inter-
ventions should not be based on evidence of their relative costs and
beneﬁts alone. NICE must consider other factors when developing
its guidance, including the need to distribute health resources in
the fairest way within society as a whole” (principle 3).The clinical guidelines program was initiated in 2001 and
since then more than 200 guidelines have been published.
Typically, they give broad guidance covering all, or speciﬁc,
aspects of the diagnosis and management of a particular con-
dition. They also incorporate any relevant technology appraisals
or interventional procedure guidance that NICE has already
produced for the condition concerned. Unlike NICE’s technology
appraisals, the clinical guidelines are not mandatory for the NHS,
but often they form the basis of the development of standards to
evaluate clinical practice.
A key feature of the clinical guidelines program is that NICE
shares the “ownership” of the program with the various “royal
colleges” of medicine, which are the central clinical associations
in the United Kingdom. Historically, the national collaborating
centers producing the guidelines have been located in the various
royal colleges, although the guidelines are produced according to
a template devised by NICE. The topics for guidelines are selected
on the basis of the need to develop quality standards and
assigned to the various collaborating centers. A scoping exercise
is then undertaken, in consultation with interested parties,
including professional societies, the NHS, the Department (min-
istry) of Health, and, if relevant, technology manufacturers. Then
a guideline development group (GDG) is appointed, comprisingociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Economics, University of York, Heslington, York YO1O 5DD, UK.
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GDG is provided with technical support, including expertise in
systematic reviews and health economics. A critical feature of the
process is to identify a number of “key clinical questions,” which
form the basis for the systematic reviews of existing evidence on
effectiveness and cost-effectiveness, plus any de novo economic
analysis in situations in which relevant cost-effectiveness evi-
dence is absent or inadequate. Typically, the GDG meets 12 times
over a period of up to 2 years. At each meeting, the GDG reviews
and discusses the clinical and economic evidence pertaining to
one to three key clinical questions.
Once completed, the guideline is circulated for extensive
consultation and is then revised before the sign-off by NICE.
Several documents are produced, the main one being a summary
of the recommendations, the “NICE guidelines.” In addition,
interested individuals can also obtain the “Full guidelines,” or,
in the newer guidelines, a range of documents that give details of
the evidence and analyses used to support the recommenda-
tions. There is also a nontechnical version, called “Information
for the public,” which can be helpful for patients and their
families. NICE also supports the implementation of the guideline
with a number of tools and resources for the NHS, the most
important ones being a “baseline assessment tool” and a “costing
statement,” which helps health authorities estimate the likely
ﬁnancial impact of adopting the recommendations in the guide-
line. The present list of published guidelines, plus those in develop-
ment, can be accessed via the NICE Web site (http://www.nice.org.
uk). The earlier guidelines are called “clinical guidelines,” and the
more recent ones are called “NICE guidelines” [2].Advantages of the Clinical Guidelines Program
The NICE clinical guidelines are probably not as widely known as
its technology appraisals, which sometimes attract attention
because they imply rationing or restrictions on the availability
of new treatments and procedures. The guidelines, however, do
have a number of important advantages. First, because the
operation of the program is shared with the medical profession,
it represents an important collaboration aimed at improving the
standard of care in the NHS. Thereby, it is more likely that clinical
opinion leaders will be willing and able to help in encouraging the
adoption of recommendations. Second, the guidelines provide an
opportunity to review all aspects of the care pathway, rather than
focusing on only the adoption of a new technology. Third, the
guidelines offer the potential to discuss disinvestment (in prac-
tices and procedures) as well as new investment.
A common criticism made of technology assessment by
health care decision makers is that it often only offers advice
on how to spend resources on new technologies and rarely
discusses how those resources can be found, especially
in situations (like the one faced by the NHS in the United
Kingdom) of having a ﬁxed budget. During the production of a
guideline, the GDG often discusses practices or procedures that
may be discontinued because they are of limited use, or can be
streamlined because they are at present being applied in an
inefﬁcient manner. Some of these suggestions are included in the
“Do not dos” list published on the NICE Web site [3].Contributions of Economic Analyses
As mentioned previously, the role of the health economist
supporting the GDG is to undertake systematic reviews of the
economic evaluation literature relevant to each of the key clinical
questions and, if necessary, conduct a de novo economic analy-
sis. Table 1 details the economic analyses conducted for theguidelines published from January 1 to August 31, 2015. The
expectation is that normally one to two new economic analyses
will be required per guideline. It can be seen that de novo analyses
were conducted to help answer at least one of the key clinical
questions for all but one of the guidelines over the period
considered here. Some of the analyses were merely costing studies,
or adaptations of existing economic analyses, but most of them
used a decision-analytic model and are comparable with the
analyses carried out in the context of NICE’s technology appraisals.
The economic analyses can support the guidelines in a
number of ways. In the case of lipid modiﬁcation (CG181), an
economic analysis was conducted to support the recommenda-
tion that a high-intensity statin (e.g., atorvastatin 20 mg daily)
should be offered for the primary prevention of cardiovascular
disease in people who have a 10% or higher 10-year risk of
developing the disease. It was thought that this recommendation
might be controversial, given the high number of individuals who
would be brought into therapy and the likely budget impact.
Extensive cost-effectiveness modeling provided a robust defense
of the recommendation on economic grounds.
In the case of bladder cancer (NG2), NICE was aware that this
is one of the most expensive cancers to manage, and so economic
considerations were potentially important. In this case, two
economic analyses were carried out. The ﬁrst analysis compared
a single instillation of chemotherapy immediately after transure-
thral resection of bladder cancer tumors versus no chemother-
apy. The study found that chemotherapy was highly cost-
effective in all risk groups. The second analysis assessed the
cost-effectiveness of reduced follow-up and/or using newer tests
and procedures compared with present practice. It was found
that reducing cystoscopic follow-up was cost-effective in low-
and intermediate-risk patients.
Therefore, taken together, these economic analyses addressed
both the potential for investment in therapy as well as the
potential disinvestment. From time to time NICE has produced
lists of items of its guidance that have the potential for cost
reductions [4]. Table 2 provides some examples of the possibil-
ities for cost reductions relating to clinical guidelines. This list is
based on costing work undertaken at the time the guidance is
published and covers all clinical guidelines from January 2005.
(Some of the earlier guidelines on the list have since been
updated and are no longer applicable.) All guidance that was
considered to deliver a net saving has been identiﬁed. There may
be elements of other guidelines that will deliver savings, but in
some circumstances fully implementing the guidance requires
investment. These ﬁgures are only estimates and are not to be
taken as NICE’s view of desirable, maximum, or minimum ﬁgures,
but they are useful in providing a sense of the scale of savings
achievable. Also, these “savings” are potential savings only. In many
cases actions will be required to realize them. NICE encourages
users of the costing templates to modify the assumptions used in
the templates to more accurately reﬂect local circumstances.Challenges and Issues for Further Discussion
Despite the attractions of introducing cost-effectiveness consid-
erations into NICE clinical guidelines, many challenges remain.
First, some economists have argued that, compared with NICE’s
technology appraisal program, the inﬂuence of economics has
been lower because of the joint ownership of the program with
royal colleges. For example, Wailoo et al. [5] argued that NICE
clinical guidelines should be subjected to independent appraisal
like the technologies considered in NICE’s technology assessment
program because the cost-effectiveness of some clinical proce-
dures might not be sufﬁciently scrutinized. Littlejohns et al. [6]
acknowledged this concern and pointed to the inevitable tension
Table 1 – Examples of de novo economic analyses in NICE clinical guidelines (January 1–August 31, 2015).
Guideline Topics studied
Gastroesophageal reﬂux disease: children and
young people (NG1)
Changes to feeding in infants
Antacids/alginates
Medical management approaches
Fundoplication surgery
Enteral tube feeding
Bladder cancer (NG2) Single instillation of chemotherapy immediately after transurethral resection of bladder
cancer tumors vs. no chemotherapy
Reduced follow-up and/or using newer tests and procedures vs. present practice
Diabetes in pregnancy (NG3) Self-management programs in women with diabetes planning a pregnancy
Screening, diagnosis, and treatment for gestational diabetes
Screening for congenital cardiac malformations
Medicines optimization (NG5) Medicine review cost analysis
Challenging behavior and learning difﬁculties
(NG11)
Parent training for the management of behavior that challenges
Psychosocial, pharmacological, and combined interventions for the management of sleep
problems
Antipsychotics for the management of behavior that challenges
Violence and aggression (NG10) None
Anemia management in people with chronic
kidney disease (NG8)
Diagnostic tests for predicting response to iron therapy
Bronchiolitis in children (NG9) Bronchodilators, corticosteroids, and in combination
Costs of CPAP and high-ﬂow oxygen
Costs of giving intravenous ﬂuids or nasogastric hydration
Hypertonic saline vs. normal saline
Suspected cancer: recognition and referral
(NG12)
Tests to diagnose colorectal cancer for patients aged 40 y and older with a change in
bowel habit
Melanoma: assessment and management
(NG14)
Sentinel node biopsy alongside wide excision vs. wide excision only (stage IA to stage IIC)
Alternative follow-up strategies in high-risk cutaneous melanoma
Diabetes (type 1 and type 2 in children and
young people) (NG18)
Multiple daily injections vs. mixed insulin injections
Different frequencies of capillary blood glucose monitoring
Blood ketone monitoring vs. urine ketone monitoring
Type 1 diabetes in adults (NG17) Long-acting insulins and once- vs. twice-daily insulin
HbA1c threshold to reduce the risk of complications
Continuous glucose monitoring vs. standard monitoring of blood glucose
CPAP, continuous positive airway pressure; HbA1c, glycated hemoglobin.
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could expect while recognizing the broader public health objec-
tives of equity, fairness, and efﬁciency. They argued that econ-
omists should be more involved in the guidelines development
process.
Second, the potential impact of economics can be lessened
because of the lack of time available to undertake de novo
analyses. On occasions, the precise topics for the economic
analyses have been identiﬁed rather late in the guidelines
development process. If, as is often the case, the existing
economics literature does not provide enough to answer the
question being proposed, then the necessary de novo analysis
can be a little rushed. Third, because the implementation of the
recommendations from clinical guidelines is not mandatory for
the NHS, it is possible that they may not be fully implemented.
NICE does encourage implementation through the development
of quality standards on the basis of the recommendations,
although ultimately implementation can be achieved only by
winning over hearts and minds. To the extent that some
recommendations are not implemented, this is likely to dilute
the impact of guidelines on improving efﬁciency.
Over time, the acceptability, prominence, and quality of
economic analyses in guidelines have increased, as evidenced
by the list of economic analyses given in Table 1. In addition, the
number of key clinical questions examined in each guideline has
been reduced, from more than 20 to around 10 to 15. This has
been partly achieved because the topics in the more recentguidelines have been narrower in scope, seldom covering the
full clinical pathway of a given disease, as was the case in many
of the earlier guidelines. Also, the key clinical questions are being
identiﬁed earlier in the guideline development process, thereby
giving the economist more time to conduct analyses if these are
needed. Finally, NICE has invested in the production of resources
and tools to facilitate the implementation of guidelines, but it is
difﬁcult to obtain accurate evidence on the extent of
implementation.Conclusions
The NICE clinical guidelines program complements the institute’s
other programs of work, which mainly address new health
technologies. Clinical guidelines offer the possibility of prioritiz-
ing topics for clinical and economic assessment on the basis of
considering the whole clinical pathway. Opportunities for dis-
investment can be considered alongside possibilities for addi-
tional investment. The guidelines development program,
however, needs to be adequately resourced, including the provi-
sion of health economists’ time to undertake the necessary
literature reviews and de novo analyses that are usually required.
Although issues in the development and use of clinical guidelines
are likely to vary by jurisdiction, NICE’s experience indicates that
it is both feasible and useful to incorporate economic
considerations.
Table 2 – Examples of potential cost reductions resulting from NICE clinical guidelines [7].
Guidance
number
Short title Why does this guidance save money? Estimated saving
per 100,000 (£)
CG34 Hypertension
(partial update
of CG18)
The recommendations update previous guidance on
prescribing drugs for hypertension. Following the revised
recommendations will cost more in drugs, but this is far
outweighed by the predicted number of cardiovascular
events (heart attacks and strokes) that will be avoided if
hypertension is better controlled.
446,627
CG30 Long-acting
reversible
contraception
The recommendations relate to offering women seeking
contraception an informed choice and access to long-
acting reversible methods. These methods are more
reliable than the oral contraceptive pill, wherein user-
error often results in unplanned pregnancy. The
additional cost of providing these methods is more than
offset by the costs of unplanned pregnancies (reduced
terminations or reduced births).
214,681
CG127 Hypertension
(update)
Following an initial investment in home blood pressure
equipment monitoring, in future years, as more people
beneﬁt from more accurate diagnoses using ambulatory
blood pressure monitoring, a cumulative effect of people
not being on antihypertensive drugs starts to be seen.
Savings from reduced treatment costs (because of not
providing treatment for people who are not truly
hypertensive) will start to outweigh the additional costs of
diagnoses from year 3.
20,464
CG108 Chronic heart
failure (partial
update)
Implementing the recommendations is anticipated to result
in increased costs for diagnosing and monitoring patients
with congestive heart failure at an earlier stage, and
increased costs for rehabilitation. This is, however, more
than offset by anticipated reductions in acute admissions
in this patient group that has frequent readmissions.
19,000
CG115 Alcohol-use-
disorders:
prevention
The guideline is one of three pieces of NICE guidance
addressing alcohol-related problems and should be read
in conjunction with PH24 (alcohol use disorders—
prevention) and CG100 (alcohol use disorders—physical
complications). It is anticipated that implementing this
guidance will lead to additional costs because of the
increase in the proportion of people with mild alcohol
dependence receiving psychological interventions and
increase in the number of people with moderate and
severe dependence receiving medication to prevent
relapse following successful withdrawal. These costs are
likely to be offset by a reduction in the number of people
who are dependent on alcohol, a reduction in the number
of people who relapse following successful withdrawal,
and by savings due to people being offered an intensive
community program rather than residential
rehabilitation.
18,600
CG107 Hypertensive
disorders
during
pregnancy
Increased costs for greater use of aspirin and monitoring of
proteinuria are considered to be more than offset by
reductions in adverse outcomes with increased costs for
treating pre-eclampsia, preterm deliveries, and babies
needing special care.
15,300
NG2 Bladder cancer:
diagnosis and
management
Savings could arise from a reduction in the number of
people with low-risk non–muscle-invasive bladder cancer
receiving follow-up cytoscopies in secondary care after 12
mo. There could be increased drug costs of giving people
suspected of low- or intermediate-risk non–muscle-
invasive bladder cancer a single dose of intravesical
mitomycin C given at the same time of a TURBT
procedure.
11,500
CG81 Breast cancer
(advanced)
One of the recommendations in this guidance
recommended a change to present practice relating to
9,690
continued on next page
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Table 2 – continued
Guidance
number
Short title Why does this guidance save money? Estimated saving
per 100,000 (£)
patients receiving trastuzumab for advanced breast
cancer. It is recommended that treatment is discontinued
if the disease progresses outside the central nervous
system. It was considered that 50% of women taking
trastuzumab and in whom the disease progresses outside
the central nervous system presently continue to take
trastuzumab. In addition to quantiﬁed savings relating to
trastuzumab, we anticipate a reduction in hospital
admissions as a result of improved treatment of patients
with bone metastases. Bone metastases account for over a
third of all nights in hospital in advanced breast cancer
care.
CG75 Metastatic spinal
cord
compression
Implementing the guidelines is anticipated to increase
surgery for the prevention and treatment of metastatic
spinal cord compression at a cost of £14 million. This is
more than offset by the reduced care costs for the
increased periods that patients keep the ability to remain
mobile. The cost difference per patient per day between
those who are able to walk and those who are immobile is
£180, a part of which is social care costs. On the basis of
those patients expected to be discharged home and cared
for in the community, a national saving of £17.5 million
was estimated.
8,974
CG69 Respiratory tract
infection in
primary care
The use of a no prescribing or a delayed prescribing policy
for a number of conditions (detailed in the guideline) is
anticipated to lead to a reduction of £3.7 million in
antibiotic prescribing nationally. In addition, there may be
beneﬁts, which are not possible to quantify, arising from
reduced use leading to less antibiotic resistance and
reduced adverse events associated with antibiotic use.
7,299
CG33 Tuberculosis Most of the savings could arise from changes recommended
in the BCG vaccination program for children between the
age of 10 and 15 y. In addition, we anticipated reduced
costs of treating active infection through better
identiﬁcation leading to reduced transmission.
7,239
CG40 Urinary
incontinence
We anticipated a reduction in the cost of urodynamic
investigations that would be carried out before
conservative treatment or surgery.
6,506
CG58 Prostate cancer A number of recommendations relating to whether to
biopsy, when to offer active surveillance, and the use of
hormonal treatments are predicted to save money. These
savings are offset by increased use of radical external
beam radiotherapy.
5,396
CG54 Urinary tract
infection in
children
A change in the cost of urine collection is estimated to cost
£2.9 million, which is offset by the anticipated reduction
of £5.0 million in the number of referrals and imaging
procedures.
4,210
CG80 Breast cancer
(early)
The recommendations relating to pretreatment ultrasound
evaluation of the axilla are considered to avoid additional
surgery if nodal disease is identiﬁed before initial surgery.
2,698
CG99 Constipation in
children and
young people
The recommendations are anticipated to increase
prescribing costs, but lead to fewer outpatient
attendances and inpatient admissions.
2,020
CG64 Prophylaxis for
infective
endocarditis
It is anticipated that a reduction in prophylactic antibiotic
prescribing will lead to reduced expenditure. In addition
to the quantiﬁed savings in antibiotics, savings from
reduced adverse effects of antibiotics such as anaphylaxis
and antibiotic resistance will occur.
1,411
CG60 Surgical
management of
OME
The recommendations are anticipated to result in a
reduction in adenoidectomies and in antibiotic
prescribing for OME.
776
continued on next page
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Table 2 – continued
Guidance
number
Short title Why does this guidance save money? Estimated saving
per 100,000 (£)
CG100 Alcohol use
disorders—
physical
complications
Implementing the guidance is anticipated to require
investment in alcohol specialist professionals (£5.9
million) and an increase in assessment and surgery for
chronic alcohol-related pancreatitis (£1 million). This is,
however, more than offset by an anticipated reduction
because of symptom-triggered drug treatment for
withdrawal (saving £7.1 million).
Assess locally
CG37 Postnatal care The annual costs have been found to vary from an initial
cost of £6.8 million to a potential saving of £1.1 million
because of the effect of increasing savings and reducing
training costs over time. The savings arise from a
reduction in the incidence of childhood disease because of
the protective effects of breast-feeding, assuming that
following the recommendations will lead to an increase in
the number of mothers who breast-feed. (See also public
health guidance on maternal and child nutrition [PH11].)
Per average unit experiencing 2,534
births per annum net savings
range £5,000–£9,000
BCG, Bacillus Calmette-Guérin; OME, otitis media with effusion; TURBT, transurethral resection of bladder tumor.
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